

03 CO  
BOX 500

TN



PATENT  
Customer No. 22,852  
New Attorney Docket No. 08201.0024-01000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Fabienne MacKay et al.

Application No.: 10/045,574

Filed: November 7, 2001

For: BAFF, INHIBITORS THEREOF  
AND THEIR USE IN THE  
MODULATION OF B-CELL  
RESPONSE AND TREATMENT  
OF AUTOIMMUNE DISORDERS

)  
)  
) Group Art Unit: 1646

)  
) Examiner: Not yet assigned

)  
)  
) CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8

) I hereby certify that this correspondence is being deposited  
) with the United States Postal Services under 37 C.F.R. § 1.8  
) on December 16, 2002 and is addressed to the Assistant  
) Commissioner for Patents, Washington, D.C. 20231.

)  
)  
)   
) Rachel Venturi

Commissioner for Patents  
Washington, DC 20231

Attention: **BOX MISSING PARTS**

Sir:

**RESPONSE TO NOTICE TO COMPLY WITH  
REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

In response to the Notice to Comply with Requirements for Patent Applications  
Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, Applicants  
submit a substitute Sequence Listing in both computer readable form and paper form for  
filing in this application and a copy of the Notice to Comply.

Please amend the specification to delete the Sequence Listing previously filed  
and to insert the attached Sequence Listing.


Applicants' representative verifies that the Sequence Listing in computer  
readable form is identical to the paper copy and that no new matter has been added  
through this submission.

Please associate the enclosed materials with the application, grant any extensions of time required to enter this response, and charge any required fees to deposit account 06-0916.

Respectfully submitted,


FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: December 16, 2002

By:   
Leslie A. McDonell  
Reg. No. 34,872

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
[www.finnegan.com](http://www.finnegan.com)



Commissioner for Patents  
Washington, DC 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/045,574	11/07/2001	Fabienne MacKay	A070 US CP

CONFIRMATION NO. 9312

## FORMALITIES LETTER



\*OC000000008959783\*

Timothy P. Linkkila  
BIOGEN, INC.  
14 Cambridge Center  
Cambridge, MA 02142

Date Mailed: 10/16/2002

# NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Filing Date Granted

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

A copy of this notice **MUST** be returned with the reply.

BIOGEN, INC. - IP DEPT

OCT 21 2001

REFERRED TO  
NOTED BY

Customer Service Center  
Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY